ABC | Volume 111, Nº5, November 2018

Short Editorial Martins Cardiovascular aggression by doxorubicin: the search for mechanisms Arq Bras Cardiol. 2018; 111(5):729-730 References This is an open-access article distributed under the terms of the Creative Commons Attribution License 1. Martins WA, Moço ETSM. Cardio-Oncology: the price of aging. Rev Bras Cardiol. 2012;25(3):164-6. 2. Ewer MS, Von Hoff DD, Benjamin RS. A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin. 2011;7(3):363-72. 3. De Vita Jr VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643-53. 4. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, etal.Riskfactorsfordoxorubicin-inducedcongestiveheartfailure.AnnIntern Med. 1979;91(5):710-7. 5. SawyerDB.Anthracyclinesandheartfailure.NEnglJMed.2013;368(12):1154-6. 6. Fraczkowska K, Bacia M, Przybyło M, Drabika D, Kaczorowska A, Rybka J, et al. Alterations of biomechanics in cancer and normal cells induced by Doxorubicin. Biomed Pharmacother. 2018 Jan;97:1195-203. 7. Souza CA, Simões R, Borges KBG, Oliveira AN, Zogeib JB, Alves B, et al. Uso da rigidez arterial para monitoramento precoce de eventos adversos cardiovasculares por antracíclicos em pacientes com câncer de mama. um estudo piloto. Arq Bras Cardiol. 2018; 111(5):721-728. 8. ReesML,KhakooAY.Molecularmechanismsofhypertensionandheartfailure due to antiangiogenic cancer therapies. Heart Fail Clin. 2011;7(3):299-311. 9. Souza VB, Silva EN, RibeiroML, MartinsWA. Hypertension in patients with cancer. Arq Bras Cardiol. 2015;104(3):246-52. 730